免疫检查点抑制剂相关外周血生物标志物的研究进展

Research progress of peripheral blood biomarkers related to immune checkpoint inhibitors

肿瘤精准治疗已经进入以免疫检查点抑制剂(ICIs)为代表的免疫治疗时代。以肿瘤组织为基础的检测,如程序性死亡受体配体-1和肿瘤突变负荷等是临床用于筛选ICIs获益人群的常见生物标志物。但基于组织的检测存在组织标本不足和需要进行有创、复杂的操作等缺陷,限制了其广泛应用,而近来兴起的外周血生物标志物为这些缺陷提供了一种非侵入性的解决方案。本综述总结了ICIs相关外周血生物标志物的研究进展,以期为临床筛选ICIs获益人群提供参考。

Precision treatment of cancer has entered the era of immunotherapy represented by immune checkpoint inhibitors(ICIs).Tumor tissue-based detection,such as programmed cell death-ligand 1 and tumor mutational burden are common biomarkers used in clinical screening for the benefit groups of ICIs.However,the wide application of tissue-based detection has been limited for insufficient tumor tissue samples and the need for invasive and complex operation.The recent rise of peripheral blood biomarkers provides an alternative non-invasive solution to address these defects.This review summarizes the research progress of peripheral blood biomarkers related to immune checkpoint inhibitors,in order to provide references in clinic for screening groups benefiting from ICIs.